JP2010503691A - ７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法 - Google Patents

７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法 Download PDF

Info

Publication number
JP2010503691A
JP2010503691A JP2009528374A JP2009528374A JP2010503691A JP 2010503691 A JP2010503691 A JP 2010503691A JP 2009528374 A JP2009528374 A JP 2009528374A JP 2009528374 A JP2009528374 A JP 2009528374A JP 2010503691 A JP2010503691 A JP 2010503691A
Authority
JP
Japan
Prior art keywords
dose
compound
substituted
body surface
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009528374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010503691A5 (US07462627-20081209-C00021.png
Inventor
サプラ，プジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of JP2010503691A publication Critical patent/JP2010503691A/ja
Publication of JP2010503691A5 publication Critical patent/JP2010503691A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
JP2009528374A 2006-09-15 2007-08-17 ７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法 Pending JP2010503691A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84493806P 2006-09-15 2006-09-15
US86451606P 2006-11-06 2006-11-06
US11/704,607 US7462627B2 (en) 2006-02-09 2007-02-09 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
PCT/US2007/076241 WO2008033643A2 (en) 2006-09-15 2007-08-17 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Publications (2)

Publication Number Publication Date
JP2010503691A true JP2010503691A (ja) 2010-02-04
JP2010503691A5 JP2010503691A5 (US07462627-20081209-C00021.png) 2011-05-06

Family

ID=39184444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009528374A Pending JP2010503691A (ja) 2006-09-15 2007-08-17 ７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法

Country Status (11)

Country Link
US (3) US7462627B2 (US07462627-20081209-C00021.png)
EP (1) EP2073809A4 (US07462627-20081209-C00021.png)
JP (1) JP2010503691A (US07462627-20081209-C00021.png)
KR (2) KR20150005721A (US07462627-20081209-C00021.png)
CN (1) CN101707888B (US07462627-20081209-C00021.png)
AU (1) AU2007297042B2 (US07462627-20081209-C00021.png)
BR (1) BRPI0716807A2 (US07462627-20081209-C00021.png)
CA (1) CA2662920A1 (US07462627-20081209-C00021.png)
IL (1) IL197122A0 (US07462627-20081209-C00021.png)
MX (1) MX2009002853A (US07462627-20081209-C00021.png)
WO (1) WO2008033643A2 (US07462627-20081209-C00021.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023095741A1 (ja) * 2021-11-25 2023-06-01 日油株式会社 医療用４分岐型水溶性ポリマー

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010025337A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
PT2349346T (pt) * 2008-09-23 2019-10-24 Nektar Therapeutics Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano).
WO2010048018A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CA2760771A1 (en) * 2009-05-04 2010-11-11 Intezyne Technologies, Incorporated Polymer micelles containing sn-38 for the treatment of cancer
US20120171201A1 (en) * 2009-07-22 2012-07-05 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2501413B1 (en) * 2009-11-18 2019-03-27 Nektar Therapeutics Acid salt forms of polymer-drug conjugates
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
KR102320753B1 (ko) 2013-10-04 2021-11-02 프로린크스 엘엘시 Sn-38 서방성 컨쥬게이트
CN104650342B (zh) * 2013-11-18 2018-07-10 江苏豪森药业集团有限公司 多支链聚合药物前体及其应用
CN108727582B (zh) * 2017-04-21 2021-11-05 博瑞生物医药（苏州）股份有限公司 靶向抗癌偶联物
AU2019206623A1 (en) 2018-01-12 2020-07-16 Prolynx Llc Synergistic cancer treatment
CN110577550A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-去甲斑蝥素结合物及其应用
WO2022035843A1 (en) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Topoisomerase inhibitors
WO2022064052A1 (en) 2020-09-28 2022-03-31 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Peptidic conjugates of sn38 useful in the treatment of cancer
WO2023186822A1 (en) 2022-03-28 2023-10-05 Hospital Sant Joan De Deu Peptidic water-soluble delivery system of anticancer drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512265A (ja) * 1998-04-17 2002-04-23 エンゾン，インコーポレーテッド 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート
WO2005028539A2 (en) * 2003-09-17 2005-03-31 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
TW438775B (en) * 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH10168373A (ja) * 1996-12-12 1998-06-23 Fuji Xerox Co Ltd インクジェット記録用インク及びそれを用いる記録方法
JP3855344B2 (ja) * 1997-02-19 2006-12-06 日本油脂株式会社 ポリオキシアルキレンカルボン酸の製造方法
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) * 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
WO2000021370A1 (en) 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
CA2356697C (en) 1999-01-06 2010-06-22 Cornell Research Foundation, Inc. Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
AU4564200A (en) * 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
CN101507820A (zh) 1999-10-12 2009-08-19 细胞治疗公司 聚谷氨酸-治疗剂结合物的生产方法
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US6632818B2 (en) 2000-01-12 2003-10-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2001257577A1 (en) * 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
CZ20023330A3 (cs) 2000-03-17 2003-02-12 Cell Therapeutics, Inc. Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US6756037B2 (en) * 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
EP1355671A2 (en) * 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
US20020123401A1 (en) 2001-03-02 2002-09-05 Henry Rassem Ragheb Combination starter-generator
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP4123856B2 (ja) * 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
JP2005507934A (ja) 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
NZ537113A (en) * 2002-06-06 2007-01-26 Univ Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
KR101476067B1 (ko) * 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US6649778B1 (en) * 2002-09-20 2003-11-18 Enzon, Inc. Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same
US7879868B2 (en) 2002-10-11 2011-02-01 Novartis Ag Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
EP1578843B1 (en) 2002-12-31 2008-07-09 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US20050214250A1 (en) * 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
WO2005089805A2 (en) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors
WO2005094332A2 (en) 2004-03-26 2005-10-13 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2007092646A2 (en) * 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512265A (ja) * 1998-04-17 2002-04-23 エンゾン，インコーポレーテッド 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート
WO2005028539A2 (en) * 2003-09-17 2005-03-31 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012063891; ＳＵＧＩＹＡＭＡ　ＫＡＴＳＵＫＩ　ＥＴ　ＡＬ: 'Ｉｒｉｎｏｔｅｃａｎ　ｈｙｄｒｏｃｈｌｏｒｉｄｅ　ｆｏｒ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｒｅｃｕｒｒｅｎｔ　ａｎｄ　ｒｅｆｒａｃｔｏｒｙ　ｎｏｎ-Ｈｏｄｇｋｉｎ　ｌｙｍｐｈｏｍａ：　ａ　ｓｉｎｇｌ' ＣＡＮＣＥＲ ｖｏｌ．　９４，　ｎｏ．　３, 20020201, ｐａｇｅｓ　５９４-６００ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023095741A1 (ja) * 2021-11-25 2023-06-01 日油株式会社 医療用４分岐型水溶性ポリマー

Also Published As

Publication number Publication date
US7462627B2 (en) 2008-12-09
US20070197575A1 (en) 2007-08-23
CA2662920A1 (en) 2008-03-20
WO2008033643A2 (en) 2008-03-20
KR20150005721A (ko) 2015-01-14
WO2008033643A3 (en) 2008-12-11
AU2007297042A1 (en) 2008-03-20
EP2073809A4 (en) 2011-04-13
IL197122A0 (en) 2009-11-18
KR20090059117A (ko) 2009-06-10
CN101707888A (zh) 2010-05-12
US20100204261A1 (en) 2010-08-12
US8299089B2 (en) 2012-10-30
US7723351B2 (en) 2010-05-25
CN101707888B (zh) 2013-05-15
BRPI0716807A2 (pt) 2013-11-05
AU2007297042B2 (en) 2013-01-10
EP2073809A2 (en) 2009-07-01
US20090074706A1 (en) 2009-03-19
MX2009002853A (es) 2009-03-27

Similar Documents

Publication Publication Date Title
JP2010503691A (ja) ７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法
JP5265384B2 (ja) 乳癌、結腸直腸癌、膵臓癌、卵巣癌及び肺癌の治療のための７−エチル−１０−ヒドロキシカンプトセシンのマルチアーム・ポリマー複合体
EP2341774B1 (en) Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8048891B2 (en) Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2005532429A (ja) カンプトテシン誘導体およびそのポリマーコンジュゲート
US20100056555A1 (en) Method of treating ras associated cancer
CN116133693A (zh) 载药的大分子及其制备方法
JP2009539879A (ja) インデノイソキノリン放出性ポリマー複合体
US11590232B2 (en) Bioconjugates of neuropeptides derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806